About Inactive ubiquitin carboxyl-terminal hydrolase MINDY-4B
Inactive ubiquitin carboxyl-terminal hydrolase MINDY-4B (MINDY4B) is a protein
from Homo sapiens identified by UniProt accession
A8MYZ0, 460 residues long.
MolForge cross-references it against 0 known binders and
4 disease associations.
Target properties
| Protein name | Inactive ubiquitin carboxyl-terminal hydrolase MINDY-4B |
|---|
| UniProt accession | A8MYZ0 |
|---|
| Gene | MINDY4B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 460 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (4)
Diseases linked to this target (Open Targets).
- stressful life event measurement · score 0.30
- neoplasm · score 0.02
- central nervous system cancer · score 0.01
- systemic lupus erythematosus · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-A8MYZ0-F1 | alphafold | PREDICTED | 83.06 | — |
Amino-acid sequence (460 residues)
MDMEVLGQEQ SSEQLDLEEI SRKISFLDKW REIFSYHRLG TNNSTPQNHE GNHTSADENE DGTGLSQPKG QGHLPSSGLC SIPNPSIISS KLGGFPISLA MATKLRQILF GNTVHVFSYN WKKAYFRFHD PSSELAFTLE VGKGGARSIQ MAVQGSIIKY LLFTRKGKDC NLGNLCEISK KEQEQALAAA LAGILWAAGA AQKATICLVT EDIYVASTPD YSVDNFTERL QLFEFLEKEA AEKFIYDHLL CFRGEGSHGV ILFLYSLIFS RTFERLQMDL DVTTTQLLQP NAGGFLCRQA VLNMILTGRA SPNVFNGCEE GKSQETLHGV LTRSDVGYLQ WGKDASEDDR LSQVGSMLKT PKLPIWLCNI NGNYSILFCT NRQLLSDWKM ERLFDLYFYS GQPSQKKLVR LTIDTHSHHW ERDQQEEKHG PRRRFSPVEM AIRTKWSEAT INWNGTVPFF
Explore Inactive ubiquitin carboxyl-terminal hydrolase MINDY-4B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets